Intravitreal bevacizumab injection for intraocular neovascularization in children

Intravitreal bevacizumab injection for intraocular neovascularization in children - Bevacizumab therapy for retinopathy of prematurity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014316

Enrollment

Registered

2014-06-20

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity

Interventions

Intravitreal bevacizumab injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with intraocular neovascularization

Exclusion criteria

Exclusion criteria: Patients with systemic risk factor

Design outcomes

Primary

Measure	Time frame
visual acuity funduscopy fluorescein fundus angiography	—

Countries

Japan

Contacts

Public ContactMasayuki Ohnaka

Kansai Medical University Ophthalmology

ohnakam@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026